TSRL, INC.

Basic Information

540 AVIS DR STE A
ANN ARBOR, MI, 48108-7906

Company Profile

n/a

Additional Details

Field Value
DUNS: 156551699
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection

    Amount: $599,360.00

    DESCRIPTION (provided by applicant): Adenovirus can be a significant health risk for immune-compromised patients, both adult and pediatric patients. In pediatric patients in particular, complications ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Broad Spectrum Antiviral Nucleoside Phosphonate Analogs

    Amount: $597,046.00

    DESCRIPTION: The Working Group for Civilian Biodefense has identified orthopox DNA viruses such as variola as a potential bioterrorism threat, and numerous other DNA viruses, including herpes, adeno, ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

    Amount: $2,585,246.00

    DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase ...

    SBIR Phase II 2011 Department of Health and Human Services
  4. Novel prodrugs for treatment of human CMV infection

    Amount: $591,457.00

    DESCRIPTION (provided by applicant): As a result of the widespread use of antiviral prophylaxis and pre-emptive therapy, the incidence and severity of human cytomegalovirus (HCMV) disease and its indi ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Development of the orally delivered, non-absorbable ACE inhibitor enalaprilat for

    Amount: $197,747.00

    DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Development of orally delivered, non-absorbable AT1 receptor antagonists for infl

    Amount: $268,620.00

    DESCRIPTION (provided by applicant): A major limitation with most current medical therapies for inflammatory bowel disease (IBD) is the indiscriminant immunosuppressive effect of these drugs. We have ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. Prodrugs of Neuraminidase Inhibitors for Increased Oral Bioavailability

    Amount: $185,621.00

    DESCRIPTION (provided by applicant): Virally-encoded neuraminidase plays a key role in the life-cycle of the influenza virus. A class of anti-influenza drugs that inhibits the action of neuraminidase ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Bile acid conjugates for improving the oral bioavailability of bisphosphonates

    Amount: $255,852.00

    DESCRIPTION (provided by applicant): Bisphosphonates are chemically and enzymatically stable analogues of inorganic pyrophosphate that interfere with specific biochemical and enzymatic pathways of the ...

    SBIR Phase I 2008 Department of Health and Human Services
  9. Improving Absorption and Targeting of Antiviral Drugs

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): With recent unsettling events foreshadowing an increased sense of urgency, NIAID has targeted research and development of therapeutics, vaccines, adjuvants/immunos ...

    SBIR Phase II 2007 Department of Health and Human Services
  10. Vidarabine Prodrugs as Anti-Pox Virus Agents

    Amount: $297,813.00

    DESCRIPTION (provided by applicant): The Working Group for Civilian Biodefense has identified smallpox as one of the most serious biological agents that could cause disease and deaths in sufficient nu ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government